InterCure (IL:INCR)
TASE:INCR
Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
514.20
>-0.01(-0.10%)
At close: 4:00 PM EST
514.20
>-0.01(-0.10%)
Day’s Range― - ―
52-Week Range225.30 - 605.00
Previous CloseN/A
Volume249.40K
Average Volume (3M)91.19K
Market Cap
₪162.57M
Enterprise Value332.85M
Total Cash (Recent Filing)₪51.58M
Total Debt (Recent Filing)₪179.34M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding54,681,335
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationA material swing to positive operating and free cash flow in 2025 reflects improved working-capital and spending discipline. Durable positive cash generation supports reinvestment, reduces near-term refinancing need, and provides a buffer to fund operations or strategic initiatives if the company sustains these improvements.
Integrated Wholesale + Retail ModelOwning both cultivation/wholesale and a branded retail/dispenser network creates vertical integration benefits: margin capture across the value chain, direct patient feedback for product development, and diversified revenue streams. This structural model enhances resilience to distribution disruptions and supports long-term commercialization.
Revenue Recovery TrendAn 11.1% revenue rebound in 2025 indicates demand stabilization and successful recovery actions. Sustained top-line growth is a prerequisite for operating leverage, margin restoration, and eventual profitability; if maintained, it strengthens pricing power and utilization of fixed-cost infrastructure over the next several quarters.
Bears Say
Sustained Net LossesMulti-year net losses and a negative net margin in 2025 signal the business has not yet reached consistent profitability. Persistent losses erode equity, constrain internal funding for growth or R&D, and increase reliance on external financing or dilution, posing a structural risk to long-term financial flexibility.
Negative Returns On EquityThree years of negative ROE indicate the company’s capital base is not generating returns for shareholders. This undermines investor confidence and can restrict access to cheaper capital markets; over time it may force strategic trade-offs between growth investment and balance-sheet preservation.
Cash Flow VolatilityVolatile cash flows complicate planning and raise refinancing risk: a single-year recovery following two years of large outflows may not be durable. If cash generation reverts, the company could struggle to fund capex, inventory, or retail expansion, undermining the operating improvements noted for 2025.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 225.30 and its highest was 605.00 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪162.57M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 73 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -62.8 earnings per share for the quarter, missing the consensus estimate of N/A by -62.8.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 54,681,335 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -62.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.696%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.